The main research question of this patient survey is to assess AF patients' preferences
associated with different attributes which describe the different available anticoagulation
treatment options (VKA or NOACs and, in case of NOACs, Apixaban, Dabigatran or Rivaroxaban).
VKA (Waran®) will be compared to Rivaroxaban.